In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

OpGen brings in $17mm through Series B round; adds $3mm

Executive Summary

OpGen Inc. (microbial whole genome sequencing) has raised $17mm in Series B funding from lead backer jVen Capital (whose rep on the board has now been promoted to chairman) and returning investors CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical, and Versant Ventures. The company will put the money towards marketing its Argus optical mapping system, which was launched this past June.
Deal Industry
  • Research, Analytical Equipment & Supplies
  • Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies